Cargando…

The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics

AIMS: Classic Hodgkin lymphoma (cHL) should be distinguished from its wide variety of histological mimics, including reactive conditions and mature B and T cell neoplasms. Thymus and activation‐related chemokine (TARC) is produced in extremely high quantities by the Hodgkin/Reed–Sternberg (HRS) tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kilsdonk, Melvin, Veldman, Carlijn, Rosati, Stefano, Plattel, Wouter, Diepstra, Arjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100154/ https://www.ncbi.nlm.nih.gov/pubmed/36345263 http://dx.doi.org/10.1111/his.14836

Ejemplares similares

Interim thymus and activation regulated chemokine versus interim (18)F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation
por: Plattel, Wouter J., et al.
Publicado: (2020)

Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
por: Veldman, Johanna, et al.
Publicado: (2021)

Insulin-Like Growth Factor 1 Receptor Is a Prognostic Factor in Classical Hodgkin Lymphoma
por: Liang, Zheng, et al.
Publicado: (2014)

T027: High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
por: Diepstra, Arjan, et al.
Publicado: (2022)

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2021)

Relationship between semiquantitative (18)F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma
por: Kahle, X. U., et al.
Publicado: (2019)

Usefulness of BATF3 Immunohistochemistry in Diagnosing Classical Hodgkin Lymphoma
por: Benckendorff, Julian, et al.
Publicado: (2021)

Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)

CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma
por: Veldman, Johanna, et al.
Publicado: (2022)

HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients
por: Tan, Geok Wee, et al.
Publicado: (2021)

Epidemiology of Classical Hodgkin Lymphoma and Its Association with Epstein Barr Virus in Northern China
por: Huang, Xin, et al.
Publicado: (2011)

HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters
por: Huang, Xin, et al.
Publicado: (2012)

Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to EBV-Associated Classic Hodgkin Lymphoma
por: Jiang, Peijia, et al.
Publicado: (2022)

Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
por: Huang, Xin, et al.
Publicado: (2010)

A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2023)

Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma
por: Visser, Lydia, et al.
Publicado: (2016)

Thymus and activation‐regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study
por: Zijtregtop, Eline A. M., et al.
Publicado: (2022)

Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment
por: Carbone, Antonino, et al.
Publicado: (2019)

The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein–Barr virus presence and location within the tumor
por: Wu, R, et al.
Publicado: (2016)

T001: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
por: Diepstra, Arjan, et al.
Publicado: (2022)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Axillary lymph nodes on PET in Hodgkin lymphoma after COVID‐19 vaccination
por: Arens, Anne I. J., et al.
Publicado: (2021)

HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
por: Huang, Xin, et al.
Publicado: (2012)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma
por: Romano, Alessandra, et al.
Publicado: (2016)

CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma
por: Sattarzadeh, Ahmad, et al.
Publicado: (2015)

Bob-1 is expressed in classic Hodgkin lymphoma
por: Abd El All, Howayda S
Publicado: (2007)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

MicroRNA signature in classical Hodgkin lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2021)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
por: Im, Soyoung, et al.
Publicado: (2022)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
por: Gholiha, Alex Reza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kjq6fbg3o8c1n5ru97uhbn09lf